Darbepoetin Alfa Aranesp® |
First Choice
|
|
MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) NICE CG114: Anaemia in chronic kidney disease NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy North of Tyne, Gateshead and North Cumbria - Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD) |
|
Epoetin zeta |
Formulary
|
MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) |
|
Epoetin alfa Eprex® |
Formulary
|
|
MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) NICE NG203: Chronic kidney disease: assessment and management NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD) |
|
Epoetin beta NeoRecormon® |
Formulary
|
|
MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) NICE NG203: Chronic kidney disease: assessment and management NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy Shared Care Guidelines for the Monitoring of Erythropoietins in the Treatment of Patients with Chronic Kidney Disease (CKD) |
|
Methoxy Polyethylene Glycol-Epoetin Beta Mircera®, Pegzerepoetin® alfa |
Formulary
|
|
MHRA Drug Safety Update (Jan 2018): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs) |
|